Chica­go-area au­toim­mune biotech gets phar­ma back­ing in $105M round for two PhII tri­als

COUR Phar­ma­ceu­ti­cals, a near­ly decade-old biotech work­ing on ther­a­pies for au­toim­mune dis­eases, said Tues­day it has raised $105 mil­lion in Se­ries A fund­ing to take …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER